Crohn's disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TNF 7
• IL-23 10
• JAK 0
• NLRP3 0
• IL-1 0
• GLP-1 0
• LRRK2 0
• IL-17 0
• IL-6 0
• MAPK 0
• PPAR 0
• CD19 3
• JNK 0
• STAT3 0
• TLR4 0
• TP53 0
• AKT 0
• AMPK 0
• BCMA 2
• CCR5 0
• IL-4 0
• NRF2 0
• SIRT1 0
• STING 0
• YAP 0
• ACE2 0
• AXL 0
• BRD4 0
• CD30 0
• CD40 0
• CD47 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0
• GIP 0
• GPX4 0
• HDAC 1
• HIF-1 0
• HMGB1 0
• IL-13 0
• IL-15 1
• KMT2A 0
• MMP-9 0
• mTOR 0
• MUC1 0
• PARP 0
• PD-1 0
• PD-L1 0
• PDE4 0
• PI3K 0
• PINK1 0
• RAS 0
• RUNX1 0
• TFEB 0
• TYK2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 2,010 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

  NCT07250815· Takeda· Updated 15 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  Study of ExoFlo for the Treatment of Perianal Fistulas

  NCT05836883· Direct Biologics, LLC· Updated 11 Aug 2026

  “Enrollment challenges.”Registry text, quoted unchanged. Source

• Withdrawn

  Autologous Stem Cells in the Management of Fistulating Perianal Crohn's Disease

  NCT06822686· Oxford University Hospitals NHS Trust· Updated 27 Jul 2026

  “Unable to obtain theatre access to carry out the trial.”Registry text, quoted unchanged. Source

• Terminated

  Rifaximin in Patients With Diabetic Gastroparesis

  NCT04254549· Mayo Clinic· Updated 22 Jun 2026

  “Sponsor discontinued placebo. Unable to meet enrollment goals.”Registry text, quoted unchanged. Source

• Terminated

  Optoacoustic Detection of Inflammation Using MSOT Device

  NCT05333978· University of Oklahoma· Updated 1 Jun 2026

  “Administrative Reasons”Registry text, quoted unchanged. Source

• Suspended

  Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

  NCT04225819· Massachusetts General Hospital· Updated 27 Apr 2026

  “Protocol is being modified.”Registry text, quoted unchanged. Source

• Terminated

  Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

  NCT04548583· The Cleveland Clinic· Updated 16 Apr 2026

  “PI left Cleveland Clinic”Registry text, quoted unchanged. Source

• Terminated

  MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

  NCT04578392· The Cleveland Clinic· Updated 16 Apr 2026

  “PI left Cleveland Clinic”Registry text, quoted unchanged. Source

• Terminated

  Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

  NCT04519697· Anthony Lembo· Updated 16 Apr 2026

  “PI left Cleveland Clinic”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Merck Sharp & Dohme LLC· Source

• An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

  NCT07923383· Sanofi· Source

• MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

  NCT06788340· Odense University Hospital· Source

• A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

  NCT07298421· Hoffmann-La Roche· Source

• Oral N-acetylglucosamine in Crohn's Disease

  NCT07225998· Johns Hopkins University· Source

• A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Eli Lilly and Company· Source

• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Eli Lilly and Company· Source

• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Eli Lilly and Company· Source

• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Janssen Research & Development, LLC· Source

• A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting

  NCT07746765· Janssen Sciences Ireland UC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 21
• Organoids 13
• Mendelian Randomization Analysis 44
• Gene Expression Profiling 48
• Sequence Analysis, RNA 6
• Exome Sequencing 4
• Proteomics 14
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 6
• Immunohistochemistry 9
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 76
• Machine Learning 36
• Deep Learning 13
• Cohort Studies 97
• Genome-Wide Association Study 58

• Multi-modal ensemble learning prediction of anti-TNF treatment response in pediatric patients with Crohn's disease using clinical, radiomic, and deep learning MR enterography features.

  Inflamm Bowel Dis, Oct 2026

• Histological aging signatures for monitoring tissue-specific aging and disease.

  Nat Med, Aug 2026

• A novel deep learning network for small bowel ulcerative lesion detection and differential diagnosis on double-balloon endoscopy images.

  Biomed Phys Eng Express, Jun 2026

• IBDome: An Integrated Molecular, Histopathological, and Clinical Atlas of Inflammatory Bowel Diseases.

  Gastroenterology, Jun 2026

• Deep learning layer-specific collagen quantification correlates with activity and is associated with outcomes in Crohn's disease.

  J Crohns Colitis, Jun 2026

• Deep learning-based quantitative histopathology of endoscopic biopsies in Crohn's disease: a retrospective cross-sectional validation study.

  Front Immunol, Jun 2026

• STAID: A Self-Refining Deep Learning Framework for Spatial Cell-Type Deconvolution with Biologically Informed Modeling.

  Adv Sci (Weinh), May 2026

• Deep Learning-Driven Analysis and Quantification of Histopathologic Features in a Dextran Sulfate Sodium-Induced Colitis Mouse Model.

  Am J Pathol, May 2026

• Artificial intelligence and capsule endoscopy.

  Rev Esp Enferm Dig, May 2026

• INTELCAPE: A Deep Learning-Powered System for Automated, High-Accuracy Crohn's Disease Diagnosis via Capsule Endoscopy.

  Clin Gastroenterol Hepatol, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.